IDL Diagnostics AB (publ) (STO:IDLDX)
Sweden · Delayed Price · Currency is SEK 0.4140
+0.0160 (4.02%)
Aug 27, 2026, 4:40 PM CET
IDL Diagnostics AB Market Cap
IDL Diagnostics AB has a market cap or net worth of 91.68 million as of August 27, 2026. Its market cap has decreased by -15.32% in one year.
Market Cap
91.68M
Enterprise Value
68.52M
Revenue
58.95M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.41
ChartMarket Cap Chart
Since May 25, 2011, IDL Diagnostics AB's market cap has increased from 16.78M to 91.68M, an increase of 446.46%. That is a compound annual growth rate of 11.77%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 26, 2026 | 91.68M | 12.75% |
| Dec 30, 2025 | 81.32M | -9.49% |
| Dec 30, 2024 | 89.84M | -10.76% |
| Dec 29, 2023 | 100.67M | -29.52% |
| Dec 30, 2022 | 142.82M | 31.17% |
| Dec 30, 2021 | 108.88M | -38.54% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Swedish Orphan Biovitrum AB | 161.21B |
| Getinge AB | 66.73B |
| Sectra AB | 52.87B |
| Medicover AB | 37.01B |
| Vivesto AB | 98.54M |
| OncoZenge AB | 98.30M |
| Annexin Pharmaceuticals AB | 96.36M |
| Prostatype Genomics AB | 96.06M |